Modulation of pathogenic CD14+/CD16+ monocytes
US8546331B2 · kind B2 · utility
6Cited by
3References
14Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 10, 2012 |
| Grant date | Oct 1, 2013 |
| Priority date | — |
| Expiry date | Jul 10, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention is based on the discovery that interleukin-1 alpha (IL-1alpha) is expressed on the proinflammatory CD14+CD16+ monocyte subset. Importantly, since IL-1alpha appears to be almost exclusively expressed on this monocyte subset and not other leukocytes, it represents an ideal marker for targeting the CD14+CD16+ monocyte subset. The effectiveness of an agent that depletes such pathogenic cells or modulates IL-1alpha function on such cells type can be monitored by assessing CD14+CD16+ monocyte levels or functionality.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.